A Two-Part, Phase 1/2a Trial to Determine the Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL) Delivered Via Convection Enhanced Delivery (CED) in Supratentorial Recurrent, Refractory, or Progressive Pediatric Ependymoma and High-Grade Glioma (HGG)

Pediatric patients 6-21 years of age with supratentorial recurrent, refractory, or progressive pediatric ependymoma and high-grade glioma (HGG) will be included in this study of treatment with Rhenium-186 Nanoliposome (186RNL). Phase 1 of the study will look to determine the maximum tolerated dose (MTD) of 186RNL in this patient population. Phase 2 of the study will use the recommended dose determined in Phase 1 to continue to look at overall response rate and progression-free survival following 186RNL treatment.

开始日期2025-09-01

申办/合作机构

Plus Therapeutics, Inc.

[+1]

NCT07098806

/ Recruiting临床1期

A Multicenter Phase 1 Study to Determine the Safety and Efficacy of Multiple Doses at Defined Intervals of Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL) Administered Via Intraventricular Catheter for Any Primary Solid Tumor Cancer With Leptomeningeal Metastases

This is an open-label, multicenter, Phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases to identify an MTD/MFD for a given dose, interval duration, and number of doses.

开始日期2025-07-02

申办/合作机构

Plus Therapeutics, Inc.

NCT05460507

/ Recruiting临床1期

A Single Arm Open Label Study to Determine the Safety and Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Recurrence of Glioma in Patients Who Received a Prior Treatment With 186RNL

This is an open-label, multicenter, Phase 1 study to establish the safety and efficacy/tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) for recurrence glioma in patients who received a prior treatment of 186RNL.

开始日期2024-12-12

申办/合作机构

Plus Therapeutics, Inc.

100 项与 Retreatment Rhenium Liposome 相关的临床结果

登录后查看更多信息

100 项与 Retreatment Rhenium Liposome 相关的转化医学

登录后查看更多信息

100 项与 Retreatment Rhenium Liposome 相关的专利（医药）

登录后查看更多信息

项与 Retreatment Rhenium Liposome 相关的文献（医药）

2012-09-04·Molecular pharmaceutics2区 · 医学

Feasibility of Eradication of Breast Cancer Cells Remaining in Postlumpectomy Cavity and Draining Lymph Nodes following Intracavitary Injection of Radioactive Immunoliposomes

2区 · 医学

Article

作者: Phillips, William T. ; Li, Shihong ; Bao, Ande ; Goins, Beth ; Hrycushko, Brian A.

Most diagnosed early stage breast cancer cases are treated by lumpectomy and adjuvant radiation therapy, which significantly decreases the locoregional recurrence but causes inevitable toxicity to normal tissue. By using a technique of preparing liposomes carrying technetium-99m ((99m)Tc), rhenium-186 ((186)Re), or rhenium-188 ((188)Re) radionuclides, as well as chemotherapeutic agents, or their combination, for cancer therapy with real time image-monitoring of pharmacokinetics and prediction of therapy effect, this study investigated the potential of a novel targeted focal radiotherapy with low systemic toxicity using radioactive immunoliposomes to treat both the surgical cavity and draining lymph nodes in a rat breast cancer xenograft positive surgical margin model. Immunoliposomes modified with either panitumumab (anti-EGFR) or bevacizumab (anti-VEGF) were remote loaded with (99m)Tc diagnostic radionuclide, and injected into the surgical cavity of female nude rats with positive margins postlumpectomy. Locoregional retention and systemic distribution of (99m)Tc-immunoliposomes were investigated by nuclear imaging, stereofluorescent microscopic imaging, and gamma counting. Histopathological examination of excised draining lymph nodes was performed. The locoregional retention of (99m)Tc-immunoliposomes in each animal was influenced by the physiological characteristics of the surgical site of individual animals. Panitumumab- and bevacizumab-liposome groups had higher intracavitary retention compared with the control liposome groups. Draining lymph node uptake was influenced by both the intracavitary radioactivity retention level and metastasis status. The panitumumab-liposome group had higher accumulation on the residual tumor surface and in the metastatic lymph nodes. Radioactive liposomes that were cleared from the cavity were metabolized quickly and accumulated at low levels in vital organs. Therapeutic radionuclide-carrying specifically targeted panitumumab- and bevacizumab-liposomes have increased potential compared to non-antibody targeted liposomes for postlumpectomy focal therapy to eradicate remaining breast cancer cells inside the cavity and draining lymph nodes with low systemic toxicity.

2008-01-01·Journal of drug targeting3区 · 医学

Imaging of¹⁸⁶Re-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis

3区 · 医学

Article

作者: Bao, Ande ; McMahan, C. Alex ; Goins, Beth A. ; McManus, Linda M. ; Phillips, William T. ; Zavaleta, Cristina L.

This study determined the biodistribution of rhenium-186 ((186)Re) encapsulated in biotin-liposomes containing patent blue dye, injected intraperitoneally (IP) with avidin in an OVCAR-3 ovarian cancer xenograft model and evaluated tumor response of this therapy with fluorine-18-fluorodeoxyglucose ((18)F-FDG) microPET imaging. Treated rats (n = 8) received an IP injection of (186)Re-blue-biotin-liposomes (1000 MBq/kg) 30 min before an IP injection of avidin (5 mg), whereas control rats (n = 4) received a sham IP injection of saline. Scintigraphic images showed that (186)Re-blue-biotin liposomes/avidin were retained in the peritoneal cavity with 18% of the original activity remaining after 5 days. From 1 to 4 weeks post-treatment, peritoneal (18)F-FDG standard uptake values decreased 30% in treatment group, yet increased 44% in control group. Total number of cells in ascites was significantly higher in control versus treatment group. Omental fat in control rats had numerous tumor cells compared with treated rats. Results show the potential for (186)Re-blue-biotin-liposome/avidin system in treating advanced ovarian cancer involving peritoneal carcinomatosis.

JOURNAL OF NUCLEAR MEDICINE

¹⁸⁶Re-liposome labeling using ¹⁸⁶Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats

作者: Phillips, William T. ; Goins, Beth ; Bao, Ande ; Negrete, George ; Klipper, Robert

Liposomes are important carriers for controlling the spatial and temporal distribution of drug mols. or other bioactive mols.Radiolabeled liposomes have potential applications in diagnostic imaging and radionuclide therapy.The purpose of this study was to develop a practical method for labeling liposomes with therapeutic rhenium radionuclides, using ¹⁸⁶Re as an example.Methods: An SNS pattern ligand, N,N-bis(2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA), and an S pattern ligand, benzene thiol (BT), were used to make 2 kinds of ¹⁸⁶Re-SNS/S complexes, ¹⁸⁶Re-BMEDA and ¹⁸⁶Re-BMEDA + BT.These ¹⁸⁶Re-SNS/S complexes were mixed with neutral liposomes encapsulating cysteine or (NH₄)₂SO₄ to prepare ¹⁸⁶Re-liposomes.The in vitro labeling stability of ¹⁸⁶Re-liposomes was investigated by incubation in 50% fetal bovine serum/50% phosphate-buffered saline, pH 7.4, at 37°C.Rat distribution studies of ¹⁸⁶Re-liposomes after i.v. injection were also performed.Results: The labeling efficiencies of ¹⁸⁶Re-liposomes were 52.9%-81.3% depending on the ¹⁸⁶Re-SNS/S complex chosen and whether cysteine- or (NH₄)₂SO₄-encapsulated liposomes were used.¹⁸⁶Re-(NH₄)₂SO₄ liposomes labeled with ¹⁸⁶Re-BMEDA had the best in vitro labeling stability in serum with 89.8% ± 3.1% of the radioactivity associated with liposomes at 24 h and 76.2% ± 5.1% at 96 h.A specific activity of 1.85 GBq (50 mCi) of ¹⁸⁶Re per 50 mg of phospholipid could be achieved with good labeling stability.Biodistributions were followed for 72 h and showed good in vivo stability for ¹⁸⁶Re-liposomes that was characterized by a slow blood clearance and a gradually increasing spleen accumulation.¹⁸⁶Re-BMEDA alone had fast blood clearance and no accumulation in spleen.Conclusion: A practical method for labeling liposomes with ¹⁸⁶Re using ¹⁸⁶Re-SNS/S complexes is described.The labeled ¹⁸⁶Re-liposomes were stable in serum and in vivo and could potentially be useful for radionuclide therapy.

项与 Retreatment Rhenium Liposome 相关的新闻（医药）

2025-07-23

·GlobeNewswire-Health Care

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Payment is part of $17.6 million award granted for leptomeningeal cancer targeted radiotherapeutic development programHOUSTON, July 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that the Company received notice of an advance payment of $1.6 million from the Cancer Prevention and Research Institute of Texas (CPRIT), the second-largest public cancer research funder globally, as part of the Company’s previously awarded $17.6 million grant. "This latest CPRIT disbursement and additional funding expected to be received over the next 12 months of approximately $6 million continues to provide significant non-dilutive financing,” said Andrew Sims, Plus Therapeutics Chief Financial Officer. “The support from CPRIT, combined with our active NIH and DoD grants reflect a strong institutional commitment to our clinical programs and strengthens our capital position for long-term growth. In addition, we continue to actively pursue additional grant opportunities.” The funding supports and accelerates the Company’s clinical development of REYOBIQ™ for the ReSPECT-LM dose optimization trial and further develops the Company’s CNSide LM diagnostic test as a key pivotal trial endpoint. About LMLeptomeningeal metastases (LM) are a rare but severe complication of advanced cancer, affecting the fluid-lined structures of the central nervous system. LM occurs in approximately 5% of patients with metastatic cancer, with breast cancer, lung cancer, and melanoma being the most common sources. Median survival is typically 2-6 months, and effective treatment options are limited, highlighting the urgent need for novel therapies. About REYOBIQ™ (rhenium Re186 obisbemeda)REYOBIQ (rhenium Re186 obisbemeda) is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. REYOBIQ has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. REYOBIQ is being evaluated for the treatment of recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer in the ReSPECT-GBM, ReSPECT-LM, and ReSPECT-PBC clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT). The Company’s ReSPECT-PBC clinical trial for pediatric brain cancer is supported by a $3 million grant from the U.S. Department of Defense’s Peer Reviewed Cancer Research Program. About Cancer Prevention & Research Institute of Texas (CPRIT)The Cancer Prevention & Research Institute of Texas (CPRIT) is a $6 billion cancer research and prevention initiative legislated in Texas. CPRIT accepts applications and award grants for a wide variety of innovative cancer-related research and product development and for the delivery of evidence-based cancer prevention programs and services by public and private entities located in Texas. CPRIT is the largest state cancer research investment in the history of the United States and the second largest cancer research and prevention program in the world with a three-part mission, established by the Texas Legislature, to invest in the research prowess of Texas universities and research organizations; create and expand life science infrastructure across the state; and expedite innovation in research and enhance the potential of breakthroughs in prevention and cures. About CNSide Diagnostic, LLCCNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the management of patients with leptomeningeal metastases. About Plus TherapeuticsHeadquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://www.plustherapeutics.com. Forward-Looking StatementsThis press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the Company’s ability to maintain the listing of its common stock on Nasdaq; risks related to a halt in trading or delisting of the Company’s common stock on Nasdaq; Medicare and private payors may not provide coverage and reimbursement or may breach, rescind or modify their contracts or reimbursement policies or delay payments; the risk that our products and services may not perform as expected; the early stage of the Company’s product candidates and therapies; the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash; the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it; market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; challenges associated with radiotherapeutic manufacturing, production and distribution capabilities necessary to support the Company’s clinical trials and any commercial level product demand; and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2024, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so. Investor ContactCORE IRinvestor@plustherapeutics.com

临床研究放射疗法快速通道

2025-07-14

·医药观澜

5年生存率不足10%！打破脑癌"魔咒"，创新疗法“组合拳”有望带来新曙光

▎药明康德编者按：恶性脑肿瘤俗称“脑癌”，胶质母细胞瘤（GBM）是中枢神经系统最常见、最具侵袭性的恶性脑癌之一。因患者致死率高、生存期短，其被认为是“致命脑癌魔咒”。过去20多年，美国FDA批准了多款脑胶质瘤相关疗法，改善了部分患者的生存状况。为攻克GBM治疗挑战，当前全球有大量创新药物管线正在推进。作为医药创新的赋能者，药明康德依托一体化、端到端的CRDMO平台，也在持续助力全球合作伙伴，加速以GBM疗法为代表的突破性疗法更快走向病患。今年以来，胶质母细胞瘤（Glioblastoma Multiforme，GBM）新药研发领域迎来了一些新的进展，涉及小分子、多肽、细胞疗法等。这些最新研发进展，为GBM患者带来了新的曙光。GBM是成人中枢神经系统中最常见、且最具侵袭性的恶性肿瘤之一。其可怕的侵袭性在于，肿瘤细胞会像树根一样深入大脑组织，难以彻底清除。而且，作为中枢神经系统肿瘤，血脑屏障的存在也让许多药物难以到达病灶，使治疗效果大打折扣。目前，GBM的治疗方法包括手术、放疗、化疗以及新兴的靶向治疗和免疫疗法，如小分子靶向疗法、抗体靶向疗法等。尽管GBM治疗近年来有所进步，但由于其高度侵袭性、高复发率和治疗耐药性等，整体临床治疗仍面临严峻挑战。数据显示，GBM患者确诊后的中位总生存期仅12～15个月，五年生存率不足10%。图片来源：123RF上百条临床管线推进，形成多元化抗脑癌“组合拳”近年来，随着科学界对胶质母细胞瘤病理生物学认识的不断深入，全球涌现出更丰富的创新研发管线。据公开资料，目前全球针对GBM的临床在研项目超过200个，覆盖小分子、抗体药物、各类偶联药物、细胞和基因疗法、核酸药物以及多肽药物等多种治疗模式。在众多GBM临床管线中，小分子占据近半数比例。它们主要针对已在其他瘤种治疗领域得到验证的靶点，包括EGFR、CDK4/6、XPO1、FGFR、PARP等。上半年小分子领域有多项进展：例如，Kazia Therapeutics年初宣布正与FDA讨论其具血脑屏障穿透能力的PI3K/Akt/mTOR通路小分子抑制剂paxalisib在治疗新诊断GBM患者的潜在注册途径。该产品已在2/3期GBM临床研究中取得积极结果，达到总生存期的主要终点。再例如，百时美施贵宝从Mirati Therapeutics收购获得的PRMT5抑制剂MRTX1719（BMS-986504）于今年3月启动了针对MTAP基因缺失的复发性GBM患者的美国1期临床研究。与此同时，包括免疫检查点抑制剂在内的抗体疗法以及相关联合疗法，是GBM临床研究的重要探索方向。数据显示，当前有几十款抗体药物正在探索用于治疗GBM的潜力，涵盖了多种在其他癌种经过验证的靶点。比如Vaximm公司今年3月公布了口服抗VEGFR-2试验性疫苗VXM01联合抗PD-L1单抗avelumab治疗胶质母细胞瘤的2a期试验积极结果，支持其进一步的临床研究。细胞和基因疗法也是GBM在研管线的重要组成部分，涵盖了DC细胞疗法、NK细胞疗法、CAR-γδ T细胞药物等类型。上半年这一领域也取得多项进展。比如Genenta Science公布的Temferon长期随访数据显示，该疗法在治疗新确诊的具未甲基化MGMT基因启动子（uMGMT）的GBM患者中，两年生存率稳定维持在29%，中位总生存期保持17个月。这是一种通过将体外基因转到自体Tie2+造血干细胞/祖细胞（HSPC）中，利用肿瘤浸润的单核细胞/巨噬细胞，将免疫调节分子递送到肿瘤微环境中的疗法，从而重塑肿瘤免疫环境并激活持续性免疫应答。放射性疗法近年来在癌症治疗领域也大放异彩。Telix Pharmaceuticals在4月公布的TLX101 2期临床试验初步结果表明，这款靶向L型氨基酸转运蛋白1（LAT-1）的放射性药物可有效穿透血脑屏障并精准辐射癌细胞，且耐受性良好。Plus Therapeutics公司今年3月宣布，其放射治疗药物Rhenium（186Re）obisbemeda治疗胶质母细胞瘤的1期临床试验结果亮眼：接受大于100 Gy该药治疗的患者的中位总生存期（OS）为17个月，是接受标准治疗患者的中位OS（8个月）的两倍多。此外，其他创新疗法也取得突破性进展。Sapience Therapeutics公司于6月公布的lucicebtide（ST101）2期临床试验数据显示，该C/EBPβ拮抗剂多肽新药在新确诊和复发性GBM患者中均表现出良好的疾病控制效果，目前已获得FDA授予的快速通道资格。此外，Laminar Pharma于3月宣布其合成油酸衍生物LAM561在新诊断GBM患者的关键性2b/3期临床试验中取得积极结果，特别是在MGMT甲基化患者中显示出无进展生存期改善趋势。MimiVax公司2月份公布的SurVaxM 2b期临床试验中期分析结果显示，这款靶向survivin的肽模拟免疫原能够有效刺激患者自身免疫反应，在控制肿瘤生长和预防复发方面展现出良好潜力。产业合力攻克挑战，力争打破致命的“脑癌魔咒”当前，GBM的新药开发过程仍面临重重挑战。作为一种中枢神经系统肿瘤，难以穿透血脑屏障、肿瘤自身的免疫抑制、肿瘤异质性、复发耐药等等，均是GBM治疗需克服的难题。当下，业界正在探索多种新的治疗策略，比如通过创新递送技术突破血脑屏障，持续探索创新药物类型的潜力，通过联合疗法改变胶质瘤免疫抑制微环境或提高疗效等等。攻克挑战，需要全行业的共同努力。作为医药创新的赋能者，药明康德多年以来通过其一体化、端到端的CRDMO平台，为包括GBM在内的广泛疾病新药研发提供全方位的支持，助力全球合作伙伴加速突破性疗法面世，早日造福病患。以突破血脑屏障挑战为例，GBM作为中枢神经系统（CNS）肿瘤，血脑屏障是药物递送的一大障碍。许多药物难以穿透血脑屏障，到达肿瘤组织，导致治疗效果不佳。因此，业界正在持续探索各种新策略。在这一领域，公开信息显示，药明康德DMPK自2009年起开始进行CNS相关研究，拥有超过15年的临床前CNS药物研发经验，建立了针对CNS药物体外血脑屏障通透性评价的特色且准确性较高的“漏斗”模型。对于主要通过被动扩散入脑的CNS药物，“漏斗”模型的评估准确性为100%。通过完善的体外、体内测试平台，药明康德DMPK能够快速、准确、高效地对CNS药物进行全方位药代动力学相关评价，筛选出具有良好的脑通透性及稳定性的CNS候选药物。根据早前公开信息，该平台已完成包括常规小分子、治疗性蛋白、寡核苷酸等新分子实体类型项目百余项，成功助力全球客户多个CNS药物进入临床阶段。再例如，在GBM的研发管线中，也有一部分研究在探索靶向蛋白降解剂（TPD）的治疗潜力，其中包含分子胶和蛋白降解靶向嵌合体（PROTAC）分子管线。在这一新兴药物分子领域，药明康德也在持续助力全球合作伙伴加速创新分子的研发进程。公开信息显示，早在近10年前，在这项技术刚刚起步之时，药明康德就开始布局相关的能力和技术，积累了丰富的成功经验，搭建起集发现、合成、分析纯化和测试等能力的一体化赋能平台。目前，该平台已成功支持超过120款TPD分子的开发，其中20余款顺利推进至临床阶段。例如，近期发表的一项研究就报道了一种新型PROTAC分子优化策略，药明康德生物学平台为该研究成功构建了HiBiT细胞系，提供了PROTAC功能验证的细胞学检验方法，并充分验证了优化型PROTAC更强有力的IDO1降解效果，为药代动力学以及最大耐受量毒性分析奠定了基础。科学探索的脚步从未停歇。从手术、放化疗到近年来的多种新兴疗法，每一步进展都承载着为全球GBM患者带来新生的希望。随着基础研究的深入、新技术的迭代升级，以及产业界的合力，战胜“致命脑癌”是可期的。期待未来更多突破性疗法从实验室走向临床，为患者带来更多生的希望。参考资料:[1] Pouyan, A., Ghorbanlo, M., Eslami, M. et al. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol Cancer 24, 58 (2025). https://doi.org/10.1186/s12943-025-02267-0版权说明：本文欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权或其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

免疫疗法临床1期临床2期并购

2025-07-10

·GlobeNewswire-Health Care

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area of central nervous system metastases Presentations will highlight the clinical utility of the company’s CNSide Cerebrospinal Fluid (CSF) Assay Platform for patients at risk for central nervous system metastases HOUSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that its wholly-owned subsidiary, CNSide Diagnostics, LLC (“CNSide”) will be showcasing two presentations at the upcoming SNO/ASCO CNS Metastases Conference on August 14-16, 2025, in Baltimore, MD. The CNSide data highlights its ability to quantify tumor cells and deliver actionable insights,” said Michael Rosol, Ph.D., Plus Therapeutics’ Chief Development Officer. “The diagnostic assay is an exciting advancement for enhancing CNS metastases management and driving therapies like REYOBIQ™ in our ReSPECT-LM dose optimization trial." Presentations: TitleCSF Tumor Cell (CSF-TC) Detection, Quantification and Biomarker Assessment Helps in Clinical Management of Breast Cancer and Non-Small Cell Lung Cancer Patients Having Leptomeningeal Disease (BIOM-04), (FORESEE Study, NCT05414123) PresenterPriya Kumthekar, M.D. Date/TimeThursday, August 14, 2025, 7:15 – 9:00 p.m. ET LocationGrand Ballroom VI TitleThe Oncogenic Flip in Patients with Leptomeningeal Metastatic Disease (LMD): Longitudinal Detection in Cerebrospinal Fluid Tumor Cells (CSF-TCs) Reveals Implications for Differential Treatment of the LMD Tumor, (BIOM-03) PresenterPriya Kumthekar, M.D. Date/TimeFriday, August 15, 2025, 3:25 – 4:50 p.m. ET LocationGrand Ballroom I-V About CNSide Diagnostic, LLC CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the management of patients with leptomeningeal metastases. About LMLeptomeningeal metastases (LM) are a rare but severe complication of advanced cancer, affecting the fluid-lined structures of the central nervous system. LM occurs in approximately 5% of patients with metastatic cancer, with breast cancer, lung cancer, and melanoma being the most common sources. Median survival is typically 2-6 months, and effective treatment options are limited, highlighting the urgent need for novel therapies. About Plus TherapeuticsHeadquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://www.plustherapeutics.com. Forward-Looking StatementsThis press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates. The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the Company’s ability to maintain the listing of its common stock on Nasdaq; risks related to a halt in trading or delisting of the Company’s common stock on Nasdaq; Medicare and private payors may not provide coverage and reimbursement or may breach, rescind or modify their contracts or reimbursement policies or delay payments; the risk that our products and services may not perform as expected; the early stage of the Company’s product candidates and therapies; the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash; the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it; market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; challenges associated with radiotherapeutic manufacturing, production and distribution capabilities necessary to support the Company’s clinical trials and any commercial level product demand; and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2024, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so. Investor ContactCORE IRinvestor@plustherapeutics.com

ASCO会议放射疗法

100 项与 Retreatment Rhenium Liposome 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑膜肿瘤	临床2期	-	Plus Therapeutics, Inc.	2023-10-10
复发性胶质瘤	临床2期	美国	Plus Therapeutics, Inc.	2015-06-03
复发性胶质母细胞瘤	临床2期	-	Plus Therapeutics, Inc.	-
家族性室管膜瘤	临床1期	-	Plus Therapeutics, Inc.	2025-09-01
高级别胶质瘤	临床1期	-	Plus Therapeutics, Inc.	2025-09-01
软脑膜转移性恶性肿瘤	临床1期	美国	Plus Therapeutics, Inc.	2021-12-06
中枢神经系统肿瘤	临床阶段不明	美国	Piramal Pharma Solutions, Inc.	-
室管膜瘤	临床申请批准	美国	Plus Therapeutics, Inc.	2025-06-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05034497 (ReSPECT-LM, GlobeNewswire) 人工标引	临床1期	软脑膜转移性恶性肿瘤	20	Rhenium (186Re) Obisbemeda	壓壓選鹽廠鹽廠膚觸壓(膚夢積繭艱網鹽鏇壓憲) = 1 dose-limiting toxicity (thrombocytopenia) observed in Cohort 5. 觸願醖鏇繭構餘窪壓顧 (膚獵鑰艱齋選鹹廠鏇憲 )	积极	2024-11-25
NCT05034497 (ReSPECT-LM, GlobeNewswire) 人工标引	临床1期	软脑膜转移性恶性肿瘤	16	Rhenium (186Re) Obisbemeda	餘衊網遞憲蓋齋範膚衊(積憲窪製顧膚窪鏇膚齋) = 壓積鹽鬱獵網襯夢築糧艱艱繭壓願網鑰憲夢簾 (積鹽繭鬱鏇鹹廠廠遞簾 ) 更多	积极	2024-08-12
NCT01906385 (ReSPECT-GBM, Corporate Publications) 人工标引	临床1/2期	复发性胶质母细胞瘤	15	186RNL	選簾壓製膚憲齋鑰鏇醖(鏇蓋艱憲觸夢觸構窪醖) = 鑰壓衊艱構壓糧蓋鹽襯獵遞憲製襯壓網鬱簾衊 (築糧憲積鹽簾鏇獵壓簾 ) 更多	积极	2023-11-20
RESPECT-GBM (SNO2023)	临床1/2期	复发性胶质瘤	27	Rhenium-186 Nanoliposome (186RNL) (186RNL dose <100 Gy)	範鹽淵廠膚壓鏇觸顧廠(網遞糧鹹鏇糧廠構糧顧) = weakness, fatigue, headache, seizure, scalp discomfort after CED 鹹願齋遞簾憲醖膚鏇選 (構選積顧積築鹽鬱遞齋 )	积极	2023-11-10
RESPECT-GBM (SNO2023)	临床1/2期	复发性胶质瘤	27	Rhenium-186 Nanoliposome (186RNL) (186RNL dose ≥100 Gy)		积极	2023-11-10
NCT05034497 (SNMMI2023)	临床1期	软脑膜转移性恶性肿瘤	-	186RNL (Rhenium-186 Nanoliposome)	壓膚蓋膚鏇襯鬱製觸範(鏇餘觸醖衊網齋淵艱構) = the most common AE was headache 蓋鏇範鬱廠繭簾壓膚選 (齋憲觸艱獵網淵範鹹餘 )	-	2023-08-28
NCT01906385 (SNMMI2023)	临床1/2期	复发性胶质瘤	-	186RNL (Rhenium-186 Nanoliposome)	鹽廠鏇齋網憲壓艱齋襯(鏇鹽衊艱醖鹹範艱餘築) = Most AEs were mild or moderate (Grade 1 or 2) and non-serious. In general, AEs were deemed by the principal investigator to be unrelated to treatment, with exception to 1 case of scalp discomfort considered related to the surgical procedure and 1 case of cerebral edema considered possibly related to ¹⁸⁶RNL and/or tapering of oral corticosteroids 鬱艱製淵醖觸廠蓋選廠 (淵構簾顧獵憲鬱鏇鹹廠 )	-	2023-08-28
NCT05034497 (ReSPECT-LM, NEWS) 人工标引	临床1/2期	脑膜肿瘤	10	186RNL	廠網顧壓淵繭鹹願築餘(夢顧獵鏇築網選醖蓋夢) = 蓋鹹簾夢鹹顧鑰願醖膚壓窪窪襯繭簾夢憲構糧 (蓋壓夢顧製繭築構選壓 ) 更多	积极	2023-08-11
NCT01906385 (Corporate Publications) 人工标引	临床1/2期	高级别胶质瘤 \| 家族性室管膜瘤	23	190RNL (Gy＜100)	網範憲顧夢鏇鹹製鏇鏇(願遞壓憲鑰淵獵醖襯淵) = The AE’s with the highest incidence included fatigue (50%), muscular weakness (33.3%), headache (33.3%), and gait disturbance (27.8%) 繭蓋膚鏇簾遞廠廠網廠 (壓網製選鹽窪鑰鏇遞淵 )	积极	2022-11-21
NCT01906385 (Corporate Publications) 人工标引	临床1/2期	高级别胶质瘤 \| 家族性室管膜瘤	23	190RNL (Gy＞100)		积极	2022-11-21
NCT05034497 (ReSPECT-LM, Corporate Publications) 人工标引	临床1期	脑膜白血病	4	186RNL	窪觸獵齋憲窪選構製網(繭網膚餘蓋壓鹹簾憲鑰) = 鏇鏇壓構淵窪壓鹹鑰範鏇夢夢網鏇醖網簾淵遞 (網顧顧衊鏇簾憲淵鹹鬱 )	积极	2022-10-19
ReSPECT-LM (EANM2022)	临床1/2期	软脑膜转移性恶性肿瘤	1	Rhenium-186 Nanoliposome (186 RNL)	選艱構艱齋鹽糧齋醖獵(壓淵蓋鑰鬱鏇蓋鬱構顧) = 鏇構鑰築製獵繭簾願願糧衊範觸範淵觸鏇築簾 (鹽艱膚鹽願壓壓淵積鏇 ) 更多	-	2022-09-22
ReSPECT-LM (EANM2022)	临床1/2期	软脑膜转移性恶性肿瘤	1	Control (unloaded liposomes)	壓獵鏇糧蓋夢簾鹹齋簾(選膚鏇衊築窪膚築蓋積) = 遞憲齋鬱顧構糧遞鹽獵鑰願餘衊鹽觸鏇網艱構 (齋鹹願鬱遞製夢蓋鏇窪 )	-	2022-09-22